Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ.

Ann Oncol. 2014 Feb;25(2):358-65. doi: 10.1093/annonc/mdt496.

2.

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.

Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525.

3.

Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.

Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F.

Clin Cancer Res. 2013 Sep 1;19(17):4685-96. doi: 10.1158/1078-0432.CCR-12-2549.

4.

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S.

Mol Oncol. 2015 Jun;9(6):1218-33. doi: 10.1016/j.molonc.2015.02.006.

5.

Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.

Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L.

Clin Cancer Res. 2008 Nov 15;14(22):7452-60. doi: 10.1158/1078-0432.CCR-08-1077.

6.

Genomic and expression analysis of microdissected inflammatory breast cancer.

Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa S, Cristofanilli M, Vermeulen P, Dirix L, Viens P, van Laere S, Bertucci F, Reuben JM, Ueno NT.

Breast Cancer Res Treat. 2013 Apr;138(3):761-72. doi: 10.1007/s10549-013-2501-6.

7.

Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.

Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P.

Cancer Res. 2004 Dec 1;64(23):8558-65.

8.

Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.

Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, Viens P, Birnbaum D.

Cancer Res. 2005 Mar 15;65(6):2170-8.

9.

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P.

J Pathol. 2004 Mar;202(3):265-73.

PMID:
14991891
10.

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

Gonçalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roché H.

Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216.

11.
12.

Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.

Diessner J, Van Ewijk R, Weiss CR, Janni W, Wischnewsky MB, Kreienberg R, Hancke K, Blettner M, Wöckel A, Schwentner L.

Arch Gynecol Obstet. 2015 Sep;292(3):655-64. doi: 10.1007/s00404-015-3691-4.

PMID:
25814296
13.

Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.

Remo A, Simeone I, Pancione M, Parcesepe P, Finetti P, Cerulo L, Bensmail H, Birnbaum D, Van Laere SJ, Colantuoni V, Bonetti F, Bertucci F, Manfrin E, Ceccarelli M.

J Transl Med. 2015 May 1;13:138. doi: 10.1186/s12967-015-0492-2.

14.

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S.

Oncotarget. 2015 May 30;6(15):13506-19.

15.
16.

Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.

Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M.

Cancer. 2011 Dec 15;117(24):5476-84. doi: 10.1002/cncr.26179.

17.

EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.

Bertucci F, Finetti P, Viens P, Birnbaum D.

Cancer Lett. 2014 Dec 1;355(1):70-5. doi: 10.1016/j.canlet.2014.09.014.

PMID:
25218596
18.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L.

Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003.

PMID:
21843921
19.

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G.

Ann Oncol. 2013 Mar;24(3):632-9. doi: 10.1093/annonc/mds339.

20.

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y.

Items per page

Supplemental Content

Support Center